Patents by Inventor Denis Deschenes
Denis Deschenes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9376418Abstract: The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.Type: GrantFiled: June 17, 2013Date of Patent: June 28, 2016Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.Inventors: Andrew M. Haidle, Sandra Lee Knowles, Solomon D. Kattar, Denis Deschenes, Jason Burch, Joel Robichaud, Matthew Christopher, Michael D. Altman, James P. Jewell, Alan B. Northrup, Marc Blouin, John Michael Ellis, Hua Zhou, Christian Fischer, Adam J. Schell, Michael H. Reutershan, Brandon M. Taoka, Anthony Donofrio
-
Patent number: 9145391Abstract: The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer.Type: GrantFiled: May 4, 2012Date of Patent: September 29, 2015Assignees: Merck Sharp & Dohme Corp., Merck Canada Inc.Inventors: Denis Deschenes, Michael D. Altman, John Michael Ellis, Christian Fischer, Andrew M. Haidle, Solomon D. Kattar, Alan B. Northrup, Adam J. Schell, Graham F. Smith, Brandon M. Taoka, Corey Bienstock, Maria Emilia Di Francesco, Anthony Donofrio, Scott Peterson, Kerrie B. Spencer, James Patrick Jewell, Amjad Ali, David Jonathan Bennett, Qun Dang, John Wai
-
Publication number: 20150148327Abstract: The invention provides certain substituted pyridines of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rcy, Cy, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.Type: ApplicationFiled: June 17, 2013Publication date: May 28, 2015Applicant: Merck Canada Inc.Inventors: Andrew M. Haidle, Sandra Lee Knowles, Solomon D. Kattar, Denis Deschenes, Jason Burch, Joel Robichaud, Matthew Christopher, Michael D. Altman, James P. Jewell, Alan B. Northrup, Marc Blouin, John Michael Ellis, Hua Zhou, Christian Fischer, Adam J. Schell, Michael H. Reutershan, Brandon M. Taoka, Anthony Donofrio, Joel Robichaud
-
Publication number: 20140249130Abstract: The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer.Type: ApplicationFiled: May 4, 2012Publication date: September 4, 2014Inventors: Denis Deschenes, Michael D. Altman, John Michael Ellis, Christian Fischer, Andrew M. Haidle, Solomon D. Kattar, Alan B. Northrup, Adam J. Schell, Graham F. Smith, Brandon M. Taoka, Corey Bienstock, Maria Emilia Di Francesco, Anthony Donofrio, Scott Peterson, Kerrie B. Spencer, James Patrick Jewell, Amjad Ali, David Jonathan Bennett, Qun Dang, John Wai
-
Publication number: 20100298347Abstract: Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.Type: ApplicationFiled: December 1, 2008Publication date: November 25, 2010Applicant: MERCK FROSST CANADA LTDInventors: Michel Belley, Denis Deschenes, Rejean Fortin, Jean-Francois Fournier, Sebastien Gagne, Yves Gareau, Jacques Yves Gauthier, Lianhai Li, Joel Robichaud, Michel Therien, Geoffrey K. Tranmer, Zhaoyin Wang
-
Patent number: 7799787Abstract: Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; fatty liver disease and cancer.Type: GrantFiled: December 18, 2006Date of Patent: September 21, 2010Assignee: Merck Frosst Canada Ltd.Inventors: Denis Deschenes, Rejean Fortin, Chun Sing Li, Renata M. Oballa, Yeeman K. Ramtohul
-
Publication number: 20100152208Abstract: Bicyclic heteroaromatic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; Type 2 diabetes; insulin resistance; hyperglycemia; Metabolic Syndrome; neurological disease; cancer; and liver steatosis. Formula (I).Type: ApplicationFiled: May 22, 2008Publication date: June 17, 2010Inventors: Serge Leger, Denis Deschenes, Rejean Fortin, Elise Isabel, David Powell
-
Publication number: 20100004245Abstract: Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.Type: ApplicationFiled: October 18, 2007Publication date: January 7, 2010Applicant: MERCK FROSST CANADA LTD.Inventors: Renata M. Oballa, Denis Deschenes, Marc Gagnon, Yves Leblanc, David Powell, Yeeman K. Ramtohul
-
Publication number: 20090118296Abstract: Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and fatty liver disease.Type: ApplicationFiled: July 18, 2006Publication date: May 7, 2009Applicant: MERCK FROSST CANADA LTD.Inventors: Cameron Black, Denis Deschenes, Marc Gagnon, Nicolas Lachance, Yves LeBlanc, Serge Leger, Chun Sing Li, Renata M. Oballa
-
Publication number: 20090088431Abstract: Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; fatty liver disease and cancer.Type: ApplicationFiled: December 18, 2006Publication date: April 2, 2009Inventors: Denis Deschenes, Rejean Fortin, Chun Sing Li, Renata M. Oballa, Yeeman K. Ramtohul
-
Patent number: 7482456Abstract: Novel substituted 8-phenylquinolines represented by Formula (I), wherein the phenyl group at the 8-position contains an aryl or heteroaryl substituent in the meta position, are PDE4 inhibitors.Type: GrantFiled: April 27, 2004Date of Patent: January 27, 2009Assignee: Merck Frosst CanadaInventors: Daniel Dube, Laurence Dube, Michel Gallant, Patrick Lacombe, Denis Deschenes, Dwight Macdonald
-
Patent number: 7348433Abstract: This invention encompasses a method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula (A) in an amount that is effective to treat the prostaglandin E mediated disease or conditionType: GrantFiled: December 11, 2002Date of Patent: March 25, 2008Assignee: Merck Frosst Canada & Co.Inventors: Daniel Dube, Denis Deschenes, Rejean Fortin, Yves Girard
-
Publication number: 20070158278Abstract: An apparatus for cleaning and/or sterilizing sand filter is provided. The apparatus comprises at least one sand filter but preferably a plurality. The apparatus comprises a clean water pipe circuit and a backwash water pipe circuit. Preferably connected to the backwash water pipe circuit is a cleaning and/or sterilizing means provider. On a regular basis and/or when it is detected that the efficiency of the filter has decreased below a certain threshold, cleaning and/or sterilizing means are added to the backwash water in order to remove unwanted particles, bacteria, oils and/or greases, metal deposits and the like that previous simple backwashes failed to remove. A method for using the apparatus thereof is also provided.Type: ApplicationFiled: January 9, 2006Publication date: July 12, 2007Inventor: Denis Deschenes
-
Patent number: 7153968Abstract: 8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal inducedType: GrantFiled: June 23, 2003Date of Patent: December 26, 2006Assignee: Merck Frosst Canada, Ltd.Inventors: Daniel Dube, Michel Gallant, Patrick Lacombe, Denis Deschenes, Laurence Dube, Yves Girard, Dwight Macdonald
-
Patent number: 7144896Abstract: 8-arylquinolines wherein the aryl group at the 8-position contains a meta one or two atom bridge to a phenyl, 5 or 6 member heteroaryl or fused bicyclic heteroaryl group, and wherein at least one of the bridge atoms is not carbon, are PDE4 inhibitors.Type: GrantFiled: March 17, 2003Date of Patent: December 5, 2006Assignee: Merck Frosst Canada Ltd.Inventors: Michel Gallant, Denis Deschenes, Daniel Dube, Laurence Dube, Patrick Lacombe, Dwight MacDonald
-
Publication number: 20060223850Abstract: Novel substituted 8-phenylquinolines represented by Formula (I), wherein the phenyl group at the 8-position contains an aryl or heteroaryl substituent in the meta position, are PDE4 inhibitors.Type: ApplicationFiled: April 27, 2004Publication date: October 5, 2006Inventors: Daniel Dube, Laurence Dube, Michel Gallant, Patrick Lacombe, Denis Deschenes, Dwight Macdonald
-
Publication number: 20050245513Abstract: 8-arylquinolines wherein the aryl group at the 8-position contains a meta one or two atom bridge to a phenyl, 5 or 6 member heteroaryl or fused bicyclic heteroaryl group, and wherein at least one of the bridge atoms is not carbon, are PDE4 inhibitors.Type: ApplicationFiled: March 17, 2003Publication date: November 3, 2005Inventors: Michel Gallant, Denis Deschenes, Daniel Dube, Laurence Dube, Patrick Lacombe, Dwight MacDonald
-
Publication number: 20050234238Abstract: 8-(biaryl) quinolines wherein the bi-aryl group at the 8-position is in a meta relationship to the quinoline group, are PDE4 inhibitors useful in the treatment of asthma, chronic bronchitis, chronic obstructive pulmonary disease, eosinophilic granuloma, psoriasis and other benign or malignant proliferative skin diseases, endotoxic shock, laminitis in horses, colic in horses, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, chronic obstructive pulmonary disease in animals, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis, ortherosclerosis, atherosclerosis, neurogenic inflammation, pain, cough, rheumatoid arthritis, ankylosing spondylitis, transplant rejection, graft versus host disease, hypersecretion of gastric acid, bacterial, fungal induced sepsis, viral induced sepsis, fungal inducedType: ApplicationFiled: June 23, 2003Publication date: October 20, 2005Inventors: Daniel Dube, Michel Gallant, Patrick Lacombe, Denis Deschenes, Laurence Dube, Yves Girard, Dwight Macdonald
-
Publication number: 20050222194Abstract: This invention encompasses a method for treating a prostaglandin E mediated disease or condition comprising administering to a mammalian patient in need of such treatment a compound of Formula (A) in an amount that is effective to treat the prostaglandin E mediated disease or condition.Type: ApplicationFiled: December 11, 2002Publication date: October 6, 2005Inventors: Daniel Dube, Denis Deschenes, Rejean Fortin, Yves Girard
-
Patent number: 6919353Abstract: 8-arylquinolines of formula (I) wherein the aryl group at the 8-position contains a meta two atom bridge to an optionally substituted phenyl or pyridyl group, are PDE4 inhibitors useful to treat asthma, chronic bronchitis, chronic obstructive pulmonary disease, arthritis, respiratory distress syndrome, allergic rhinitis, neurogenic inflammation, pain, rheumatoid arthritis, and other diseases. R1-R7 and Ar are as in claim 1.Type: GrantFiled: June 26, 2002Date of Patent: July 19, 2005Assignee: Merck Frosst Canada & Co.Inventors: Daniel Dube, Yves Girard, Dwight MacDonald, Anthony Mastracchio, Michel Gallant, Patrick Lacombe, Denis Deschenes